Literature DB >> 25050887

Hypocretin (orexin) neuromodulation of stress and reward pathways.

William J Giardino1, Luis de Lecea2.   

Abstract

Hypocretin (also known as orexin) is a peptide neuromodulator that is expressed exclusively in the lateral hypothalamic area and plays a fundamental role in wakefulness and arousal. Chronic stress and compulsive drug-seeking are two examples of dysregulated states of hyperarousal that are influenced by hypocretin transmission throughout hypothalamic, extended amygdala, brainstem, and mesolimbic pathways. Here, we review current advances in the understanding of hypocretin's modulatory actions underlying conditions of negative and positive emotional valence, focusing particularly on mechanisms that facilitate adaptive (and maladaptive) responses to stressful or rewarding environmental stimuli. We conclude by discussing progress toward integrated theories for hypocretin modulation of divergent behavioral domains.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25050887      PMCID: PMC4267967          DOI: 10.1016/j.conb.2014.07.006

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  54 in total

1.  Amygdalar orexinergic-GABAergic interactions regulate anxiety behaviors of the Syrian golden hamster.

Authors:  Ennio Avolio; Raffaella Alò; Antonio Carelli; Marcello Canonaco
Journal:  Behav Brain Res       Date:  2010-11-11       Impact factor: 3.332

2.  Hypocretin/orexin signaling in the hypothalamic paraventricular nucleus is essential for the expression of nicotine withdrawal.

Authors:  Ainhoa Plaza-Zabala; África Flores; Rafael Maldonado; Fernando Berrendero
Journal:  Biol Psychiatry       Date:  2011-08-10       Impact factor: 13.382

Review 3.  Convergent regulation of locus coeruleus activity as an adaptive response to stress.

Authors:  Rita J Valentino; Elisabeth Van Bockstaele
Journal:  Eur J Pharmacol       Date:  2008-01-19       Impact factor: 4.432

4.  Excitatory action of hypocretin/orexin on neurons of the central medial amygdala.

Authors:  A Bisetti; V Cvetkovic; M Serafin; L Bayer; D Machard; B E Jones; M Mühlethaler
Journal:  Neuroscience       Date:  2006-09-22       Impact factor: 3.590

5.  Interactions between VTA orexin and glutamate in cue-induced reinstatement of cocaine seeking in rats.

Authors:  Stephen V Mahler; Rachel J Smith; Gary Aston-Jones
Journal:  Psychopharmacology (Berl)       Date:  2012-03-13       Impact factor: 4.530

6.  Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine.

Authors:  Minoru Narita; Yasuyuki Nagumo; Seiko Hashimoto; Michiko Narita; Junaidi Khotib; Mayumi Miyatake; Takeshi Sakurai; Masashi Yanagisawa; Tomoya Nakamachi; Seiji Shioda; Tsutomu Suzuki
Journal:  J Neurosci       Date:  2006-01-11       Impact factor: 6.167

7.  Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: involvement of the ventral tegmental area.

Authors:  Nicole M Vittoz; Craig W Berridge
Journal:  Neuropsychopharmacology       Date:  2006-02       Impact factor: 7.853

8.  Centrally administered orexin-A activates corticotropin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus and central amygdaloid nucleus of rats: possible involvement of central orexins on stress-activated central CRF neurons.

Authors:  Fumihiko Sakamoto; Seiji Yamada; Yoichi Ueta
Journal:  Regul Pept       Date:  2004-05-15

Review 9.  Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction.

Authors:  Gary Aston-Jones; Rachel J Smith; Gregory C Sartor; David E Moorman; Lema Massi; Pouya Tahsili-Fahadan; Kimberlei A Richardson
Journal:  Brain Res       Date:  2009-10-06       Impact factor: 3.252

10.  The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration.

Authors:  Subhashini Srinivasan; Jeffrey A Simms; Carsten K Nielsen; Steven P Lieske; Jade J Bito-Onon; Henry Yi; Frederic Woodward Hopf; Antonello Bonci; Selena E Bartlett
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

View more
  30 in total

1.  Hypocretin/orexin antagonists decrease cocaine self-administration by female rhesus monkeys.

Authors:  Richard W Foltin; Suzette M Evans
Journal:  Drug Alcohol Depend       Date:  2018-05-25       Impact factor: 4.492

2.  Accumbal D2 cells orchestrate innate risk-avoidance according to orexin signals.

Authors:  Craig Blomeley; Celia Garau; Denis Burdakov
Journal:  Nat Neurosci       Date:  2017-11-27       Impact factor: 24.884

3.  Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area.

Authors:  Vijayakumar Mavanji; Claudio E Perez-Leighton; Catherine M Kotz; Charles J Billington; Sairam Parthasarathy; Christopher M Sinton; Jennifer A Teske
Journal:  Sleep       Date:  2015-09-01       Impact factor: 5.849

Review 4.  A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?

Authors:  Morgan H James; Stephen V Mahler; David E Moorman; Gary Aston-Jones
Journal:  Curr Top Behav Neurosci       Date:  2017

5.  Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression.

Authors:  Clarissa D Staton; Jazmine D W Yaeger; Delan Khalid; Fadi Haroun; Belissa S Fernandez; Jessica S Fernandez; Bali K Summers; Tangi R Summers; Monica Sathyanesan; Samuel S Newton; Cliff H Summers
Journal:  Neuropharmacology       Date:  2018-09-18       Impact factor: 5.250

Review 6.  Lateral hypothalamic area neuropeptides modulate ventral tegmental area dopamine neurons and feeding.

Authors:  Patricia Perez-Bonilla; Krystal Santiago-Colon; Gina M Leinninger
Journal:  Physiol Behav       Date:  2020-05-31

Review 7.  Hubs and spokes of the lateral hypothalamus: cell types, circuits and behaviour.

Authors:  Patricia Bonnavion; Laura E Mickelsen; Akie Fujita; Luis de Lecea; Alexander C Jackson
Journal:  J Physiol       Date:  2016-07-19       Impact factor: 5.182

8.  Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats.

Authors:  Alessandra Matzeu; Rémi Martin-Fardon
Journal:  Neuropharmacology       Date:  2019-12-04       Impact factor: 5.250

9.  Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol.

Authors:  Rachel I Anderson; David E Moorman; Howard C Becker
Journal:  Handb Exp Pharmacol       Date:  2018

10.  Intermittent Short Sleep Results in Lasting Sleep Wake Disturbances and Degeneration of Locus Coeruleus and Orexinergic Neurons.

Authors:  Yan Zhu; Polina Fenik; Guanxia Zhan; Rebecca Somach; Ryan Xin; Sigrid Veasey
Journal:  Sleep       Date:  2016-08-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.